Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification and Characterization of Small-Molecule IRF3-Dependent Immune Activators for Pharmaceutical Development.

ACS chemical biology·2022

Same author

APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.

Cancer immunology, immunotherapy : CII·2021

Same author

CpG preconditioning reduces accumulation of lysophosphatidylcholine in ischemic brain tissue after middle cerebral artery occlusion.

Analytical and bioanalytical chemistry·2020

Same author

Preconditioning in the Rhesus Macaque Induces a Proteomic Signature Following Cerebral Ischemia that Is Associated with Neuroprotection.

Translational stroke research·2018

Same author

Translational Stroke Research: Vision and Opportunities.

Stroke·2017

Same author

Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury.

Translational stroke research·2017

Search research articles

Related Experiment Video

Updated: May 13, 2026

Strategies for Study of Neuroprotection from Cold-preconditioning

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

Steps to translate preconditioning from basic research to the clinic.

Frances R Bahjat¹, Raffaella Gesuete, Mary P Stenzel-Poore

¹Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon.

Translational Stroke Research

|March 19, 2013

Summary

Preconditioning strategies, including brief ischemia or pharmacological agents, protect against ischemia-reperfusion (I/R) injury. This review explores preclinical validation steps for these promising I/R injury therapies.

Keywords:

MCAO Preconditioning animal models of stroke brain injury cardiovascular disease cerebral ischemia ischemia ischemic brain injury mouse nonhuman primate occlusion repercussion stroke therapeutic toll-like receptors

More Related Videos

Thermal Preconditioning During Ex-vivo Lung Perfusion for the Rehabilitation of Damaged Lung Grafts before Transplantation

Thermal Preconditioning During Ex-vivo Lung Perfusion for the Rehabilitation of Damaged Lung Grafts before Transplantation

Published on: October 31, 2025

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

Related Experiment Videos

Last Updated: May 13, 2026

Strategies for Study of Neuroprotection from Cold-preconditioning

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

Thermal Preconditioning During Ex-vivo Lung Perfusion for the Rehabilitation of Damaged Lung Grafts before Transplantation

Thermal Preconditioning During Ex-vivo Lung Perfusion for the Rehabilitation of Damaged Lung Grafts before Transplantation

Published on: October 31, 2025

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents

Published on: June 2, 2015

Area of Science:

Cardiovascular and Cerebrovascular Research
Neuroprotection Strategies
Pharmacological Preconditioning

Background:

Ischemia-reperfusion (I/R) injury is a major target in treating cardiovascular and cerebrovascular diseases.
Preconditioning, involving brief ischemia or pharmacological agents, confers protection against I/R injury.
Preconditioning reveals endogenous neuroprotective mechanisms and offers therapeutic potential.

Purpose of the Study:

To examine preclinical validation processes for preconditioning agents.
To discuss the challenges and strategies in translating preclinical findings to human clinical studies.
To highlight the importance of robust preclinical data for therapeutic development.

Main Methods:

Review of experimental findings on preconditioning paradigms.
Analysis of preclinical drug development pathways.
Discussion of multi-factorial data analysis from diverse disciplines.

Main Results:

Preconditioning demonstrates significant potential for preventing I/R injury.
Diverse preclinical studies are crucial for reducing clinical translation risks.
No single pathway guarantees success in therapeutic development.

Conclusions:

Preconditioning agents hold promise for clinical I/R injury prevention.
Rigorous and diverse preclinical validation is essential for therapeutic success.
Developing novel treatments requires urgency and a high tolerance for failure.